Valeant Pharma's stock jumps on report of Bausch & Lomb deal
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals, the acquisitive Canadian drug company, is reportedly close to a deal to buy eye care specialist Bausch & Lomb for $9 billion.